189 related articles for article (PubMed ID: 24093324)
1. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.
Strobl FF; Brechtel K; Schmehl J; Zeller T; Reiser MF; Claussen CD; Tepe G
J Endovasc Ther; 2013 Oct; 20(5):699-706. PubMed ID: 24093324
[TBL] [Abstract][Full Text] [Related]
2. Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
Alcocer F; Novak Z; Combs BR; Lowman B; Passman MA; Mujib M; Jordan WD
J Vasc Surg; 2014 Apr; 59(4):950-5. PubMed ID: 24491238
[TBL] [Abstract][Full Text] [Related]
3. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
Park SH; Rha SW; Choi CU; Kim EJ; Oh DJ; Cho YH; Choi WG; Lee SJ; Kim YH; Choi SH; Kim WH; Kim KC; Cho JH; Kim JH; Kim SM; Bae JH; Bong JM; Kang WY; Baek JY; Seo JB; Chung WY; Park MW; Her SH; Suh J; Kim MW; Kim YJ; Choi HJ; Soh JW;
Trials; 2014 Sep; 15():355. PubMed ID: 25208688
[TBL] [Abstract][Full Text] [Related]
5. Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
Brener SJ; Steinhubl SR; Berger PB; Brennan DM; Topol EJ;
J Invasive Cardiol; 2007 Jul; 19(7):287-90. PubMed ID: 17620671
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
[TBL] [Abstract][Full Text] [Related]
7. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty.
Cassar K; Ford I; Greaves M; Bachoo P; Brittenden J
Br J Surg; 2005 Feb; 92(2):159-65. PubMed ID: 15609386
[TBL] [Abstract][Full Text] [Related]
9. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
[TBL] [Abstract][Full Text] [Related]
10. High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
Bernlochner I; Jaitner J; Fries V; Dommasch M; Mayer K; Ott I; Langwieser N; Fusaro M; Laugwitz KL; Kastrati A; Ibrahim T
Vasa; 2016; 45(2):155-61. PubMed ID: 27058802
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the clopidogrel-proton pump inhibitor interaction after peripheral endovascular intervention for claudication.
Meltzer AJ; Da Silva P; Schneider DB; Shrikhande GV
Vasc Endovascular Surg; 2012 Oct; 46(7):524-9. PubMed ID: 22989428
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ;
Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428
[TBL] [Abstract][Full Text] [Related]
16. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Yusuf S; Zhao F; Mehta SR; Chrolavicius S; Tognoni G; Fox KK;
N Engl J Med; 2001 Aug; 345(7):494-502. PubMed ID: 11519503
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Lee SW; Chun KJ; Park SW; Kim HS; Kim YH; Yun SC; Kim WJ; Lee JY; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Jon S; Cho YH; Lee NH; Kim JH; Park SJ
Am J Cardiol; 2010 Jan; 105(2):168-73. PubMed ID: 20102913
[TBL] [Abstract][Full Text] [Related]
18. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty.
Cassar K; Bachoo P; Ford I; Greaves M; Brittenden J
J Vasc Surg; 2005 Aug; 42(2):252-8. PubMed ID: 16102623
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
